First patient treated in fifth cohort of Anixa’s ovarian cancer trial

Anixa Biosciences has treated the first patient in the fifth cohort of its Phase I clinical trial evaluating a new CAR-T therapy for recurrent ovarian cancer. The patient received a 1×10⁷/kg CAR-positive cells dose after lymphodepletion. The trial is enrolling adult women with recurrent ovarian cancer after at least two previous therapies. Credit: Jo Panuwat D / Shutterstock.com. Anixa Biosciences has treated the first patient in the fifth cohort of its Phase I clinical trial evaluating a new chimeric antigen receptor T-cell (CAR-T) therapy for recurrent ovarian cancer. Liraltagene autoleucel (lira-cel), the CAR-T candidate under investigation, is designed to target…

Source: Clinical Trials Arena